Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2007 / Cilt: 17 - Sayı: 4

The results of patients with uterine sarcoma treated with adjuvant radiotherapy

Uterus sarkomlarında adjuvan radyoterapi sonuçlarımız

Pages
209–214
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Age, menapousal status, stage, histology, grade, lymph node and lymphovascular involvement, chemotherapy were not found to be statistically significant prognostic factor for disease control and overall survival in univariate and multivariate analysis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to analyse prognostic factors and treatment results of patients with uterine sarcoma.
📊
Key Findings & Data:Between 1999–2007, twenty women treated with postoperative radiotherapy were evaluated retrospectively.
💡
Conclusion & Impact:Age, menapousal status, stage, histology, grade, lymph node and lymphovascular involvement, chemotherapy were not found to be statistically significant prognostic factor for disease control and overall survival in univariate and multivariate analysis.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Leyomiyosarkom · Geriyedönük çalışma · Uterus neoplazmları

Abstract

We aimed to analyse prognostic factors and treatment results of patients with uterine sarcoma. Between 1999–2007, twenty women treated with postoperative radiotherapy were evaluated retrospectively. Mean age was 47 years (29- 73). Median follow-up was 34 months (12-84). All patients were treated with postoperative radiotherapy. Histopathologic examination showed: leiomyosarcoma in 11 patients, endometrial stromal sarcoma in 7 and carcinosarcoma in 2. Stage IB, IC, IIIA, IIIB and IIIC tumors were identified in 4, 10, 3, 1 and 2 patients, respectively. At the time of analysis, 4 patients were dead due to progressive disease; 1 patient was alive with disease and 15 were alive without disease, with a median survival of 75 months. Age, menapousal status, stage, histology, grade, lymph node and lymphovascular involvement, chemotherapy were not found to be statistically significant prognostic factor for disease control and overall survival in univariate and multivariate analysis. This study demostrated that adjuvant radiotherapy was effective and tolerable treatment to improve locoregional control.

Özet

Uterus Sarkomlu hastalarda prognostik faktörlerin ve tedavi sonuçlarının değerlendirilmesi amaçlandı. 1999–2007 yılları arasında postoperatif radyoterapi uygulanan yirmi hasta geriye dönük olarak değerlendirildi. Ortalama yaş 47 (29-73) ve izlem süresi 34 (12-84) aydı. Hastaların tümüne postoperatif radyoterapi uygulandı. Histopatolojik tanı: 11 hastada Leimyosarkom, 7 hastada Endometrial stromal sarkom ve 2 hastada Karsinosarkom’du. Hastaların evrelere göre dağılımı: dördü Evre IB, onu evre IC, üçü IIIA, biri IIIB, ikisi ise IIIC idi. Halen hastalardan 15’i hastalıksız, 1’i hastalıklı yaşarken, 4’ü hastalığa bağlı kaybedildi. Ortalama sağ kalım 75 aydı. Tek ve çok değişkenli analiz sonucunda: menapoz durumunun, yaşın, FIGO evresinin, gradın, nekroz varlığının, lenf nodu tutulumunun, lenfovasküler invazyon varlığının, kemoterapi uygulanmasının hastalıksız sağ kalım ve genel sağ kalım için prognostik önemi istatistiksel olarak gösterilemedi. Bu çalışma adjuvan radyoterapinin uterus sarkomlarında lokal-bölgesel kontrolü sağlamada etkili ve tolere edilebilir bir tedavi olduğunu gösterdi.

🔖

Cite This Article

KORCUM, A., AKSU, G., ÖZDOĞAN, M., ŞİMŞEK, T., ERDOĞAN, G., TUNÇEL, N. (2007). The results of patients with uterine sarcoma treated with adjuvant radiotherapy. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 17 - Sayı: 4, 209–214. https://ajindex.com/articles/323230

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204-208, 2004
  2. Moskovic E, Macsweeney E, Law M, et al. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 66:1009-1015, 1993
  3. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71:1702-1709, 1993
  4. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98:176-186, 2003
  5. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 20:2758-2760, 2002
  6. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 346:1832-1833, 2002
  7. Viereck V, Huschmand Nia A, Pauer HU, et al. Diagnosis and therapy of uterine sarcoma. Zentralbl Gynakol 124:506-510, 2002
  8. Evans HL, Chawla SP, Simpson C, et al. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 62: 2239-2247, 1988
  9. Chauveinc L, Deniaud E, Plancher C, et al. Uterine sarcomas: the Curie institute experience. Prognosis factors and adjuvant treatments. Gynecol Oncol 72:232-237, 1999
  10. Gadducci A, Sartori E, Landoni F, et al. The prognostic relevance of histological type in uterine sarcoma. Cooperation task force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 23:295-299, 2002
  11. Livi L, Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol 16:261- 268, 2004
  12. Coquard R, Romestaing P, Ardiet J, et al. Uterine sarcoma managed by surgery followed by radiation therapy. Clinical outcome, prognostic factors and role of radiation therapy. Bull Cancer 6:625-629, 1997
  13. Husseiny G, Al Bareedy N, Mourad WA, et al. Prognostic factors and treatment modalities in uterine sarcoma.Am J Clin Oncol 25:256-260, 2002
  14. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96: 889- 892, 1989
  15. Dunton JC, Kelsten ML, Brooks SE, et al. Lowgrade stromal sarcoma: DNA flow cytometric analysis and estrogen progesterone receptor data. Gynecol Oncol 37:268-275, 1990
  16. Nola M, Babic D, Ilic J, et al. Prognostic parameters for survival pati